NasdaqCM:SMTI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	89	-1	N/A	N/A	1
12/31/2024	77	-6	N/A	N/A	1
3/31/2024	68	-5	-3	-3	N/A
12/31/2023	65	-4	-4	-3	N/A
9/30/2023	63	-8	-3	-3	N/A
6/30/2023	60	-9	-4	-6	N/A
3/31/2023	54	-6	-6	-5	N/A
12/31/2022	46	-8	-6	-6	N/A
9/30/2022	38	-7	-8	-7	N/A
6/30/2022	30	-8	-9	-6	N/A
3/31/2022	27	-10	-6	-6	N/A
12/31/2021	24	-8	-6	-5	N/A
9/30/2021	22	-5	-5	-4	N/A
6/30/2021	20	-4	-3	-3	N/A
3/31/2021	17	-4	-4	-3	N/A
12/31/2020	16	-4	-6	-4	N/A
9/30/2020	14	-6	-6	-4	N/A
6/30/2020	13	-5	-6	-4	N/A
3/31/2020	13	-4	-6	-4	N/A
12/31/2019	12	-3	-4	-2	N/A
9/30/2019	11	-1	-2	-1	N/A
6/30/2019	10	0	-1	-1	N/A
3/31/2019	9	0	0	0	N/A
12/31/2018	9	0	0	1	N/A
9/30/2018	8	0	1	1	N/A
6/30/2018	7	0	0	0	N/A
3/31/2018	7	0	0	0	N/A
12/31/2017	6	0	N/A	0	N/A
9/30/2017	6	0	N/A	0	N/A
6/30/2017	6	0	N/A	1	N/A
3/31/2017	6	-1	N/A	0	N/A
12/31/2016	6	-1	N/A	0	N/A
9/30/2016	4	-1	N/A	0	N/A
6/30/2016	4	-2	N/A	-1	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	3	-2	N/A	-1	N/A
9/30/2015	3	-1	N/A	-1	N/A
6/30/2015	3	-2	N/A	-1	N/A
3/31/2015	3	-2	N/A	-1	N/A
12/31/2014	3	-3	N/A	-2	N/A
9/30/2014	2	-4	N/A	-2	N/A
6/30/2014	2	-5	N/A	-2	N/A
3/31/2014	2	-4	N/A	-2	N/A
12/31/2013	2	-4	N/A	-2	N/A
9/30/2013	2	-3	N/A	-1	N/A
6/30/2013	2	-3	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SMTI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SMTI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SMTI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SMTIの収益 ( 15% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: SMTIの収益 ( 15% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SMTIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Sanara MedTech 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased by 18% to US$49.00

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

Consensus forecasts updated

No longer forecast to breakeven

Recent updates

Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story

Sanara MedTech Inc. Announces CEO Changes

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.14 loss in 1Q 2023)

Sanara MedTech Inc. to Report Q1, 2024 Results on May 13, 2024

Sanara MedTech Inc., Annual General Meeting, Jun 12, 2024

Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q4, 2023 Results on Mar 25, 2024

Price target decreased by 18% to US$49.00

Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 3Q 2022)

Sanara MedTech Inc. to Report Q3, 2023 Results on Nov 13, 2023

Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sanara MedTech Inc. (NasdaqCM:SMTI) acquired Certain Assets Related to its Collagen Products Business from Applied Nutritionals, LLC, The Hymed Group Corporation, and Dr. George Petito for 25.3 million.

High number of new directors

Sanara MedTech Inc. Elects Robert Desutter as Board of Director

Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sanara MedTech Inc. to Report Q1, 2023 Results on May 15, 2023

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Forecast breakeven date pushed back to 2024

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. Announces Resignation of Shawn M. Bowman as President, Strategic Partnerships

Forecast to breakeven in 2023

Sanara MedTech Inc. to Report Q3, 2022 Results on Nov 14, 2022

President of Strategic Partnerships notifies of intention to sell stock

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech reports Q2 results

Sanara MedTech Inc. to Report Q2, 2022 Results on Aug 15, 2022

Sanara MedTech Inc acquired Scendia Biologics, LLC from Ryan Phillips for $7.4 million.

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Sanara MedTech: Technology For Faster Healing Wounds

Third quarter 2021 earnings released: US$0.27 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.18 loss in 2Q 2020)

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.39 loss in 1Q 2020)

Neil Cataldi From Blueprint Discusses Sanara MedTech

Full year 2020 earnings released: US$0.76 loss per share (vs US$1.32 loss in FY 2019)

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

New 90-day low: US$30.00

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Sanara MedTech Inc. Appoints Sara Ortwein as Director

New 90-day high: US$41.35

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day high: US$34.24

Sanara MedTech Inc Appoints Bob Desutter to the Company's Board of Directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘